Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations with government - PBS
The Supreme Court rejected appeals from drug manufacturers challenging Medicare price negotiations, upholding the government's ability to negotiate drug prices under the Inflation Reduction Act.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers with high-spend Medicare drugs, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate: CMS will announce first set of negotiated prices by September 1, 2024, with implementation in 2026. Prepare now.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The Supreme Court's decision removes a legal barrier, allowing Medicare to proceed with price negotiations for selected drugs, which will cap prices and reduce revenue for manufacturers.
Who it affects
Branded drug makers with high-spend Medicare drugs, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Review your drug portfolio for potential inclusion in Medicare negotiation; assess financial impact and adjust pricing strategies; engage with CMS on negotiation process.
Deadline
Immediate: CMS will announce first set of negotiated prices by September 1, 2024, with implementation in 2026. Prepare now.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines